Drug intelligence / Profile preview

lacticaseibacillus rhamnosus g7

Development stage: Preclinical
Lead developer: Guangdong Ocean University
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral, Vaginal

Overview

Lacticaseibacillus rhamnosus G7 is a novel probiotic strain isolated from the yogurt of herdsmen in Qinghai Province, China. [1] It is being investigated for its potential to prevent and treat ulcerative colitis (UC). In a preclinical mouse model of DSS-induced colitis, oral administration of the G7 strain was shown to alleviate disease symptoms, including weight loss and colon shortening. [1] The mechanism of action involves modulating the host immune system and the gut microbiota. [1] Specifically, L. rhamnosus G7 reduces the serum levels of pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α, while increasing the anti-inflammatory cytokine IL-10. [1] It also helps rebalance the composition of the intestinal flora by increasing the abundance of beneficial bacteria like *Faecalibaculum* and decreasing the abundance of *Bacteroides* and *Escherichia_Shigella*. [1] In vitro evaluations confirmed the strain has a good safety profile and tolerance to gastric acid and bile salts, suggesting its viability as an oral probiotic. [1]

Other names: Lacticaseibacillus rhamnosus G7

Beyond the preview

Go deeper on lacticaseibacillus rhamnosus g7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lacticaseibacillus rhamnosus g7.

Explore the full profile